Wall Street Zen lowered shares of Turn Therapeutics (NASDAQ:TTRX – Free Report) from a hold rating to a sell rating in a research note issued to investors on Saturday,Wall Street Zen reports.
Several other equities research analysts also recently issued reports on the stock. Zacks Research upgraded shares of Turn Therapeutics to a “hold” rating in a research note on Tuesday, July 21st. LADENBURG THALM/SH SH raised Turn Therapeutics to a “strong-buy” rating in a research report on Monday, July 20th. Lucid Cap Mkts upgraded Turn Therapeutics to a “strong-buy” rating in a research note on Thursday. Weiss Ratings cut Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 18th. Finally, WBB Securities reiterated a “sell” rating and set a $10.00 target price on shares of Turn Therapeutics in a research note on Monday, September 14th. Two equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $9.00.
Check Out Our Latest Analysis on TTRX
Turn Therapeutics Stock Performance
Turn Therapeutics (NASDAQ:TTRX – Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.20) EPS for the quarter. As a group, research analysts anticipate that Turn Therapeutics will post -0.4 EPS for the current year.
Institutional Trading of Turn Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of TTRX. Ieq Capital LLC acquired a new position in Turn Therapeutics in the 2nd quarter valued at about $1,660,000. DDFG Inc lifted its position in Turn Therapeutics by 34.9% during the first quarter. DDFG Inc now owns 70,534 shares of the company’s stock worth $226,000 after acquiring an additional 18,246 shares during the last quarter. BlackRock Inc. acquired a new stake in Turn Therapeutics during the second quarter worth approximately $282,000. Bridgewater Advisors Inc. bought a new stake in shares of Turn Therapeutics during the second quarter worth approximately $242,000. Finally, Jefferies Financial Group Inc. bought a new stake in shares of Turn Therapeutics during the second quarter worth approximately $119,000.
About Turn Therapeutics
We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.
Read More
- Five stocks we like better than Turn Therapeutics
- 3 Defense Stocks Riding Nuclear, Missile, and Aerospace Demand
- SoFi Is Bypassing the Banking Bottleneck With Stablecoin Settlement
- These 3 Overlooked Stocks Have Big Money Behind Them
- Darden Restaurants Serves Up Fresh Catalysts for a Stock Price Rally
Receive News & Ratings for Turn Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turn Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
